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Therapeutic drug monitoring may be useful in tuber-
culosis management, but programmatic implementation is 
understudied. We performed a retrospective cohort study to 
determine prevalence of lower than expected levels of isoni-
azid, rifampin, ethambutol, and pyrazinamide measured at 
time of estimated peak serum concentration. Patients were 
tested for serum concentration at 2 hours after medication 
administration. When patients were tested, 22 had concen-
trations lower than expected range for rifampin, 23 of 39 
patients had low levels of isoniazid, and 8 of 26 patients had 
low levels of ethambutol; all 20 patients tested for pyrazi-
namide were within expected range. Over 26 months, 42 
patients met criteria for slow response. Diabetes was as-
sociated with slow response (p<0.001), and persons with 
diabetes were more likely than persons without diabetes to 
have low rifampin levels (p = 0.03). Dosage adjustment of 
rifampin was more likely to elevate serum concentration to 
the target range than adjustment of isoniazid given in daily 
doses (p = 0.01). 
W
orldwide, tuberculosis (TB) remains the leading 
cause of death from a curable infectious disease; 
≈1.4 million deaths occurred in 2008 alone (1). Death is 
a consequence of delayed diagnosis and ineffective or in-
complete treatment because cure rates exceed 95% with 
appropriate therapy (2). Slow response to therapy can lead 
to prolonged infectiousness, extended treatment duration, 
acquired drug resistance, or recurrence of TB after treat-
ment. The reasons for slow response are diverse, but mea-
surement of serum anti-TB drug levels, or therapeutic drug 
monitoring (TDM), is a potentially useful tool for uncover-
ing the causes of slow response (3,4). Low serum levels 
can be a consequence of malabsorption, inaccurate dosing, 
altered metabolism, or drug–drug interactions (4), but in 
most instances low serum levels can be readily corrected 
with dose adjustment.
TDM is currently recommended in TB treatment guide-
lines as optional (5), and few large TB control programs 
have access to routine TDM. Although published reports 
describe patients for whom slow response was attributable 
to low drug levels, questions remain about how best to im-
plement TDM on a programmatic scale (6,7). Deﬁ  nitions of 
slow response vary, and recommendations for which medi-
cations to prioritize for TDM are lacking. Furthermore, for 
general populations receiving TB therapy, TDM is unlikely 
to be of beneﬁ  t, given the infrequency of treatment failure 
or TB recurrence (8). Although it is well known that certain 
patients, such as those infected with HIV and thus prone to 
malabsorption, are at higher risk for low drug levels (9–12), 
studies of TDM that included patients responding well to 
anti-TB medications found lower than expected drug levels 
of isoniazid and rifampin in many patients with adequate 
clinical response (13,14). Therefore, identiﬁ  cation of pa-
tients at risk for slow response is critical within a TB con-
trol program. In addition, TDM performed earlier in the 
time course of slow response may also affect other major 
programmatic outcomes, such as treatment duration.
In the state of Virginia it is mandatory for providers to 
report all cases of TB to the Virginia Department of Health. 
Each case is assigned to a nurse case manager, who oversees 
and monitors the progress of each patient until treatment is 
completed. Directly observed therapy is administered by 
the nurse case manager or a trained outreach worker. After 
4 weeks of therapy, patients are screened by the nurse case 
manager. Medical consultation for patients with ongoing 
symptoms is provided by the state TB clinicians in an effort 
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to identify slow response earlier and to prevent acquired 
drug resistance. Clinicians deﬁ  ne slow response in a patient 
as after >30 days from the start of treatment the patient has 
>2 of the following ﬁ  ndings: sputum smear positive for ac-
id-fast bacilli; no improvement in TB-speciﬁ  c symptoms, 
including fever, cough, weight loss, and/or night sweats; 
and no improvement in chest radiograph lesions previously 
identiﬁ  ed as consistent with TB. Routine TDM among pa-
tients who met criteria for slow response was instituted by 
March 2007.
We performed a retrospective cohort study among pa-
tients slow to respond to pulmonary TB treatment in the 
state of Virginia to determine the prevalence of lower than 
expected levels of isoniazid, rifampin, ethambutol, and 
pyrazinamide measured at the time of estimated peak se-
rum concentration (Cmax). Secondary aims included inves-
tigation of risk factors for levels below the expected range, 
evaluation of the mean change and likelihood of achieving 
a level within the expected range after dose adjustment, 
and comparison of outcomes between persons with slow 
responses with those with low and expected levels. The 
study was approved by the institutional review boards for 
human subjects research at the University of Virginia and 
the Virginia Department of Health.
Methods
Patients
Patients were identiﬁ  ed for inclusion in the study by 
using routine TB surveillance data recorded in the Virgin-
ia TB Registry. All patients who were >18 years of age, 
had conﬁ  rmed Mycobacterium tuberculosis cultures, and 
started TB therapy in the state of Virginia during March 
1, 2007–May 1, 2009, were eligible. We included patients 
who had been treated for pulmonary TB or pulmonary TB 
and extrapulmonary TB and who began a regimen of iso-
niazid, rifampin, ethambutol, and pyrazinamide. All M. tu-
berculosis specimens were sent to the state TB laboratory, 
where drug-susceptibility testing was performed after sec-
ondary culture of the isolate by using the automated Bactec 
MGIT 960 system (Becton Dickinson, Sparks, MD, USA). 
Patients were excluded if their original isolate was later 
found to be resistant to >1 ﬁ  rst-line medication. Patients 
were also excluded if they had TDM performed for reasons 
other than slow response.
Surveillance data were retrieved from the state TB 
registry and included demographics (age, sex, race/eth-
nicity, country of origin, and homelessness), TB history 
(prior episodes of TB, sputum smear and culture status of 
current TB episode, and chest radiograph abnormalities), 
coexisting conditions (diabetes, HIV infection, intrave-
nous drug use, and excessive alcohol use), and treatment 
outcomes (completion of TB treatment, duration of com-
pleted TB treatment, relapse of TB following treatment 
completion, acquisition of drug resistance in a previously 
susceptible TB strain, and death from any cause during 
TB treatment). Information about medication-related ad-
verse events following anti-TB drug dose increase was 
obtained from personal communication with the state TB 
medical consultants.
Therapeutic Drug Monitoring 
The standard procedure for TDM was for patients to 
be given their daily dose of TB medications in the morning 
while fasting and then observed for 2 hours, during which 
they were restricted from eating or drinking. At 2 hours af-
ter medication administration, venous blood was collected 
and serum was separated before transport on dry ice to the 
regional referral laboratory. The drug levels from blood col-
lected 2 hours after medication administration (C2hr) were 
used as the estimated peak maximum serum concentration 
(Cmax) as per standard practice and were determined by us-
ing high-performance liquid chromatography (for isoniazid 
and rifampin) or gas chromatography with mass spectrom-
etry (for ethambutol and pyrazinamide). Expected C2hr 
ranges were provided and were consistent with published 
norms (5). C2hr levels were also recorded for patients with 
initial low levels in whom follow-up TDM was performed 
after dose adjustment.
Data Analysis 
Demographic and clinical characteristics were com-
pared with the χ2 statistic or, for nonparametric data, 
the Mann-Whitney U test. For the determination of risk 
factors for C2hr levels below the expected range, values 
were dichotomized into normal if the value was within or 
above the expected range, or low if the value fell below 
the expected range. Bivariate and multivariate logistic 
regression analyses were used to determine risk factors 
for either a low isoniazid or a low rifampin level. The 
multivariate model included any variable with p<0.1 in 
bivariate analysis and relevant demographic characteris-
tics. Paired Student t tests were used to report the mean 
change in C2hr levels following dose adjustment. Medica-
tions dosed >5× per week were considered daily dosed. 
Biweekly dosing was used for some patients for isoniazid 
and rifampin, with the isoniazid biweekly dose at 3× the 
usual daily dose. The rifampin dose was unchanged re-
gardless of dosing frequency. The log-rank test was used 
to compare treatment duration and for patients who had 
not completed therapy at the time of analysis; data were 
right censored for survival analysis. All tests of signiﬁ  -
cance were 2 sided. Data were analyzed with SPSS ver-
sion 17.0 software (SPSS Inc., Chicago, IL, USA).
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Results
During the study, 350 patients were treated with an 
initial regimen of isoniazid, rifampin, ethambutol, and 
pyrazinamide for pulmonary TB; of these patients, 45 
(13%) met criteria for slow response. Thirty-seven patients 
were excluded from the study (34 with normal response 
and 3 with slow response) after drug-susceptibility test-
ing showed resistance to >1 medication of the treatment 
regimen. An additional 2 patients were excluded because 
TDM was performed for reasons other than slow response. 
Thus, 311 patients were included in the study, of whom 42 
(14%) met criteria for slow response (Table 1). At the time 
of TDM among patients meeting criteria for slow response, 
all had persistent TB-related symptoms. Of the 23 patients 
with initial smear-positive sputum specimens, 17 (74%) 
had specimens that remained smear positive.
The mean (SD) age for patients in the study was 46 
years (20 years), and 204 (65%) were men (Table 1). The 
most common ethnicity was Asian (102 [33%]) and 228 
(73%) were foreign born. Among all patients, 291 (93%) 
had no history of TB. Most patients tested had a positive 
tuberculin skin test (TST) result, although 85 (27%) did not 
have a TST reading recorded. There were 287 patients with 
a sputum smear recorded at the time of diagnosis; of these 
smears, 193 (62%) were positive for acid-fast bacilli. Nine-
ty-ﬁ  ve percent (295) of patients had a chest radiograph with 
ﬁ  ndings suggestive of TB, of which 122 (39%) were cavi-
tary. There was no signiﬁ  cant difference in the proportion 
of patients with a positive TST result, a positive sputum 
smear, or a chest radiograph showing cavitation among the 
42 with a slow response and the remaining patients with ad-
equate response. Among patients meeting criteria for slow 
response, none were HIV infected and none reported us-
ing illicit drugs (either intravenous or nonintravenous). The 
only signiﬁ  cant predictor of slow response was diabetes 
(unadjusted odds ratio [OR] 6.5, 95% conﬁ  dence interval 
[CI] 3.2–13.5, p<0.001; adjusted OR [aOR] 6.3, 95% CI 
2.8–14.0, p<0.001).
Initial C2hr Levels 
All 42 patients who were slow to respond were moni-
tored for rifampin, and 22 (52%) had a C2hr level below the 
expected range; 1 (2%) had a high level (Figure 1). For 
daily or biweekly dosed rifampin, the median C2hr level 
was 7.4 μg/mL (interquartile range [IQR] 2.5–11.4 μg/
mL, expected range 8–24 μg/mL) (Table 2). Thirty-nine 
patients were monitored for isoniazid; 23 (59%) had lev-
els below the expected range. For daily dosed isoniazid, 
the median C2hr was 1.90 μg/mL (IQR 1.1–3.5 μg/mL, ex-
pected range 3–6 μg/mL), and for biweekly dosing, 9.8 μg/
mL (IQR 2.8–11.2 μg/mL, expected range 9–18 μg/mL). 
Among the 39 patients who were tested for isoniazid and 
rifampin levels, 13 (33%) had levels below the expected 
range for both medications. Twenty-six patients were 
monitored for ethambutol; 8 (31%) had levels below the 
expected range. The median C2hr level for ethambutol was 
2.5 μg/mL (IQR 1.7–3.2 μg/mL, expected range 2–6 μg/
mL). Twenty patients were monitored for pyrazinamide, all 
had levels within the expected range; median C2hr level was 
28.1 μg/mL (IQR 26.5–33.2 μg/mL, expected range 20–50 
μg/mL).
Risk Factors for Low Isoniazid or Rifampin Levels
Analyses of risk factors for low levels of isoniazid or 
low levels of rifampin were performed, but small sample 
size precluded meaningful analysis of risk factors for low 
ethambutol levels. Patients with diabetes were at signiﬁ  -
cantly increased risk of having a low rifampin level (OR 
5.8, 95% CI 1.4–23.1, p = 0.01; aOR 5.7, 95% CI 1.2–25.7, 
p = 0.03) (Table 3). Patients who received isoniazid biweek-
ly were less likely to have low isoniazid levels than those 
who received isoniazid daily, but this association was not 
statistically signiﬁ  cant in multivariate analysis (OR 0.21, 
95% CI 0.05–0.91, p = 0.04; aOR 0.47, 95% CI 0.09–2.5, 
p = 0.37) (Table 3).
Follow-up C2hr Levels after Dose Adjustment 
Eighteen patients with rifampin levels below the ex-
pected range had follow-up TDM after dose adjustment. 
Levels for all patients increased from the initial to the 
follow-up level with a mean (SD) change of 11.0 μg/mL 
(9.7 μg/mL; p<0.001); 16 (89%) had levels in the expected 
range after the ﬁ  rst dose adjustment (Figure 2). Fourteen pa-
tients had follow-up TDM for daily-dosed isoniazid levels 
below the expected range; monitoring detected increased 
levels in 12 patients, with a mean (SD) change of 3.4 μg/
mL (2.9 μg/mL; p = 0.001); 4 (29%) patients had levels in 
the expected range. Four patients had follow-up TDM for 
biweekly-dosed isoniazid levels below the expected range, 
and all had increased levels with a mean (SD) change of 
11.8 μg/mL (6.1 μg/mL; p = 0.03); 3 (75%) patients had 
levels in the expected range.
Rifampin levels below the expected range were sig-
niﬁ  cantly more likely to be corrected to within the expected 
range following the ﬁ  rst dose adjustment than were daily-
dosed isoniazid levels below the expected range (p = 0.01). 
There was no signiﬁ  cant difference in the likelihood of cor-
rection to the expected range between daily and biweekly 
dosed isoniazid. No follow-up levels of ethambutol or 
pyrazinamide were reported. There were no reported medi-
cation-related adverse events following dose increase.
Treatment Outcomes 
Complete outcomes were available for 32 (76%) pa-
tients; 10 patients continued receiving treatment. Twenty-
seven patients successfully completed treatment, 3 patients 
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Table 1. Baseline characteristics of adults treated for drug-susceptible pulmonary TB in a state control program, Virginia, USA, March 
1, 2007–May 1, 2009* 
Characteristic
All patients, N = 311, 
no. (%) 
Slow response, 
n = 42, no. (%) 
Normal response,  
n = 269, no. (%) 
Bivariate OR (95% CI);  
p value 
Age, y 
  18–39  151 (49)  16 (38)  135 (50)  Referent 
  40–64  90 (29)  13 (31)  77 (29)  1.4 (0.65–3.10); p = 0.38 
 > 65 70 (22)  13 (31)  57 (21)  1.9 (0.87–4.30); p = 0.11 
Sex
  M  204 (65)  29 (69)  175 (65)  Referent 
  F  107 (35)  13 (31)  94 (35)  0.84 (0.42–1.70); p = 0.61 
Race/ethnicity
  Asian  102 (33)  19 (45)  83 (31)  Referent 
  Hispanic  82 (26)  11 (26)  71 (26)  0.67 (0.30–1.50); p = 0.34 
  Black  86 (28)  8 (19)  78 (29)  0.45 (0.19–1.10); p = 0.07 
  White  41 (13)  4 (10)  37 (14)  0.47 (0.15–1.50); p = 0.20 
 Native  American  0 0 0
Foreign born 
  No  83 (27)  9 (21)  74 (28)  Referent 
  Yes  228 (73)  33 (79)  195 (72)  1.4 (0.64–3.00); p = 0.41 
Homeless
  No  301 (97)  41 (98)  260 (97)  Referent 
  Yes  10 (3)  1 (2)  9 (3)  0.71 (0.09–5.70); p = 0.74 
Illicit drug use 
  No  298 (96)  42 (100)  256 (95)  Referent 
  Non-injection use  7 (2)  0 7 (3)  p>0.99 
  Injection use  6 (2)  0 6 (2)  p>0.99 
Alcohol abuse 
  No  276 (89)  38 (91)  238 (89)  Referent 
  Yes  35 (11)  4 (9)  31 (11)  0.81 (0.27–2.40); p = 0.70 
HIV status
  Negative   266 (86)  37 (88)  229 (85)  Referent 
  Positive   11 (3)  0 11 (4)  p>0.99 
  Unknown  34 (11)  5 (12)  29 (11)  1.1 (0.39–2.90); p = 0.90 
Diabetes
  No  270 (87)  25 (60)  245 (91)  Referent 
  Yes  41 (13)  17 (40)  24 (9)  6.9 (3.3–14.6); p<0.001† 
Prior TB history 
  No  291 (93)  38 (91)  253 (94)  Referent 
  Yes  18 (6)  3 (7)  15 (5)  1.3 (0.37–4.80); p = 0.66 
  Unknown  2 (1)  1 (2)  1 (1)  6.6 (0.41–108.70); p = 0.18 
Tuberculin skin test result 
  Negative  47 (15)  5 (12)  42 (16)  Referent 
  Positive  179 (58)  23 (55)  156 (58)  1.2 (0.44–3.50); p = 0.68 
  Unavailable  85 (27)  14 (33)  71 (26)  1.7 (0.56–4.90); p = 0.36 
Sputum smear 
  Negative  94 (30)  9 (21)  85 (31)  Referent 
  Positive  193 (62)  30 (72)  163 (61)  1.7 (0.79–3.80); p = 0.17 
  Not done  24 (8)  3 (7)  21 (8)  1.3 (0.34–5.40); p = 0.67 
Chest radiograph 
  No TB findings  16 (5)  2 (5)  14 (5)  Referent 
  Noncavitary  173 (56)  19 (45)  154 (57)  0.86 (0.18–4.10); p = 0.85 
  Cavitary  122 (39)  21 (50)  101 (38)  1.5 (0.31–6.80); p = 0.64 
Disease site 
  Pulmonary  212 (68)  32 (76)  180 (67)  Referent 
  Pulmonary/extrapulmonary  99 (32)  10 (24)  89 (33)  0.63 (0.30–1.30); p = 0.23 
*Tuberculin skin test values recorded in surveillance database as positive based on guidelines from the American Thoracic Society and Centers for 
Disease Control and Prevention (15). TB, tuberculosis; OR, odds ratio; CI, confidence interval. 
†Adjusted odds ratio 6.3 (95% CI 2.8–14.0); p<0.001.  RESEARCH
died, and 2 patients moved out of the state where follow-
up was incomplete. Median time to completion of therapy 
among all 27 patients was 45 weeks (IQR 40–51 weeks). 
Among the 14 patients with initial rifampin levels below 
the expected range who completed treatment, the median 
duration was 40 weeks (IQR 38–48 weeks) compared with 
a median duration of 47 weeks (IQR 44–55 weeks) for the 
13 patients with initial rifampin levels within the expected 
range (log-rank p = 0.17).
There were no reports of relapse of infection over a me-
dian of 14.5 months (IQR 7–25 months) from the conclu-
sion of treatment. No patient had documented acquisition 
of medication resistance in follow-up TB cultures while 
on treatment. All 3 deaths occurred shortly after TDM was 
performed: 1 patient had isoniazid, rifampin, ethambutol, 
and pyrazinamide levels within expected ranges, 1 patient 
had isoniazid, rifampin, and ethambutol levels within ex-
pected ranges, and 1 patient had isoniazid, rifampin, and 
ethambutol levels below the expected ranges.
Discussion
The major ﬁ  nding of this study is that among patients 
being treated for pulmonary TB in Virginia, most patients 
that met criteria for slow response to therapy were found 
to have C2hr levels of rifampin and isoniazid below the ex-
pected range; many patients also had low levels of etham-
butol. Given the high frequency of patients who were slow 
to respond to both key ﬁ  rst-line medications, isoniazid and 
rifampin, and the well-tolerated subsequent increase in lev-
els documented after dose adjustment, TDM appears to be 
a useful strategy for identifying a remediable cause of slow 
response at a programmatic level. Furthermore, the median 
duration of therapy for patients with rifampin levels below 
the expected range was nearly 2 months shorter than that 
for patients with normal rifampin levels. Although it is not 
speciﬁ  cally known if identiﬁ  cation and correction of lower 
than expected levels brought about a rapid improvement in 
TB clinical signs and symptoms, the comparatively shorter 
course represents a substantial cost savings when consider-
ing personnel involved in monitoring and medication ad-
ministration, as well as diagnostic tests averted in the work-
up of otherwise unexplained slow response.
We found that ≈90% of patients with lower than ex-
pected rifampin levels who were subsequently tested after 
the ﬁ  rst dose adjustment achieved target levels. Dose-titra-
tion studies of rifampin conﬁ  rm a continuously increasing 
response of early bactericidal activity by measurement of 
sputum colony counts with corresponding increase in ri-
fampin dose (16,17). Rifampin has been tolerated at doses 
as high as 1,200 mg in small studies, and larger trials are 
ongoing to study high-dose rifampin in an effort to shorten 
therapeutic duration (18,19). Given increasing evidence 
that rifampin may be underdosed for many patients regard-
less of TB outcome (20), the ﬁ  ndings of this study suggest 
that rifampin is a prime medication to prioritize for early 
TDM for patients for whom TB therapy is failing.
Diabetes was signiﬁ  cantly associated with slow re-
sponse in our study population, and, among persons with 
a slow response with diabetes, C2hr levels of rifampin were 
signiﬁ  cantly more likely to be below the expected range. 
Patients with diabetes are at greater risk for incident TB 
(21,22) and are more likely to have poor TB treatment out-
comes (23,24), which may partially be explained by inad-
equate pharmacotherapy. A growing body of evidence has 
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Figure 1. Results of serum concentration 2 hours after medication 
administration levels (C2hr) of ﬁ  rst-line antituberculosis medications 
among patients with a slow response to tuberculosis therapy. 
Frequencies are reported for low, within target, and high C2hr levels 
corresponding to levels below, within, or above the expected range 
for each medication.
Table 2. Comparison of median serum concentration at 2 hours after medication administration as estimate of peak serum 
concentration levels and expected range, therapeutic drug monitoring, Virginia, USA, March 1, 2007–May 1, 2009* 
Medication Median serum concentration, μg/mL (IQR) Expected serum concentration range, μg/mL 
Isoniazid
 Daily  1.9  (1.1–3.5)  3–6
 Biweekly  9.8  (2.8–11.2)  9–18 
Rifampin daily and/or biweekly  7.4 (2.5–11.4)  8–24 
Ethambutol† 2.5 (1.7–3.2)  2–6
Pyrazinamide† 28.1 (26.5–33.2)  20–50 
*IQR, interquartile range. 
†All patients with therapeutic drug monitoring levels obtained for ethambutol and pyrazinamide were taking weight-based daily doses of these 
medications. Monitoring for Slow Response to TB Treatment
demonstrated reduced rifampin exposure in patients with 
TB and diabetes, which may be in part related to impaired 
absorption (25,26). Although rifampin absorption may not 
be blunted by delayed gastric emptying (27), hyperglyce-
mia can decrease gastric hydrochloric acid secretion, which 
results in a higher gastric pH and reduced rifampin absorp-
tion (25). Markers of glycemic control were not available 
for analysis in this study, but it may be of further use to risk 
stratify patients with diabetes based on disease severity. It 
is suspected, though not tested, that drug–drug interactions 
were also playing a role in the observed lower levels of ri-
fampin in patients with diabetes from our study population. 
Given preexisting knowledge of the association between 
diabetes and poor treatment outcome, there may have been 
a bias on behalf of the TB control staff to characterize a pa-
tient with diabetes as a person with a slow response based 
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Table 3. Risk factors for INH or RIF serum concentration levels below the expected range 2 hours after medication administration
among persons with slow responses, therapeutic drug monitoring, Virginia, USA, March 1, 2007–May 1, 2009* 
Characteristic











Low RIF,  
n = 22,
no. (%) 
Bivariate risk ratio (95% CI); 
p value 
Age, y
  18–39   4 (25)  8 (35)  Referent  5 (25)  10 (46)  Referent 
  40–64  7 (44)  8 (35)  0.57 (0.12–2.80); p = 0.49  8 (40)  7 (32)  0.44 (0.10–1.90); p = 0.27 
 > 65 5 (31)  7 (30)  0.70 (0.13–3.70); p = 0.67  7 (35)  5 (22)  0.36 (0.07–1.70); p = 0.20 
Sex
  M  11 (69)  15 (65)  Referent  13 (65)  15 (68)  Referent 
  F  5 (31)  8 (35)  1.2 (0.30–4.60); p = 0.82  7 (35)  7 (32)  0.87 (0.24–3.10); p = 0.81 
Race/Ethnicity
  White  1 (6)  3 (13)  1.9 (0.16–22.30); p = 0.61  3 (15)  1(5)  0.37 (0.3–4.2); p = 0.42 
  Asian  7 (44)  11 (48)  Referent  10 (50)  9 (41)  Referent 
  Hispanic/Latino  6 (38)  4 (17)  0.42 (0.09–2.10); p = 0.43  3 (15)  8 (36)  3.0 (0.60–14.70); p = 0.18 
  Black  2 (12)  5 (22)  1.6 (0.24–10.60); p = 0.63  4(20)  4 (18)  1.1 (0.21–5.80); p = 0.90 
Foreign-born 
  No  3 (19)  6 (26)  Referent  6 (30)  3 (14)  Referent 
  Yes  13 (81)  17 (74)  0.65 (0.14–3.10); p = 0.59  14 (70)  19 (86)  2.7 (0.58–12.80); p = 0.21 
Diabetes
  No  10 (63)  13 (57)  Referent  16 (80)  9 (41)  Referent 
  Yes  6 (37)  10 (43)  1.3 (0.35–4.70); p = 0.71  4 (20)  13 (59)  5.8 (1.4–23.1); p = 0.01† 
Alcohol abuse
  No  15 (94)  22 (96)  Referent  18 (90)  20 (91)  Referent 
  Yes  1 (6)  1 (4)  0.69 (0.40–11.70); p = 0.79  2 (10)  2 (9)  0.90 (0.12–7.10); p = 0.92 
Dose interval
  Daily  8 (50)  19 (83)  Referent  11 (65)  16 (73)  Referent 
  Biweekly  8 (50)  4 (17)  0.21 (0.05–0.90); p = 0.04‡  6 (35)  6 (27)  0.88 (0.23–3.30); p = 0.85 
*INH, isoniazid; RIF, rifampin; CI, confidence interval. Low is defined as below expected range; normal is defined as within or above expected range. 
†Adjusted odds ratio 5.7 (1.2–25.7); p = 0.03. 
‡Adjusted odds ratio 0.47 (0.09–2.50); p = 0.37. 
Figure 2. Results in patients with initial serum concentrations 2 h after medication below the expected range with follow-up levels after 
dose adjustment for rifampin daily or biweekly (A), isoniazid daily (B), and isoniazid biweekly (C). The median initial and follow-up doses 
of rifampin daily or biweekly were 600 mg and 900 mg, respectively; for isoniazid daily, 300 mg and 450 mg, respectively; and for isoniazid 
biweekly, 900 mg and 1,200 mg, respectively. Brackets represent expected ranges for each dose of medication.  RESEARCH
on symptom persistence. Nevertheless, our ﬁ  ndings raise 
the possibility of TB programs studying the beneﬁ  t of rou-
tine TDM for rifampin among all patients with diabetes at 
the start of TB therapy.
Routine TDM among persons with slow responses 
at a relatively early point in the treatment course reﬂ  ects 
policy change within Virginia’s TB control program. Giv-
en the high prevalence of low levels of key medications 
and the observed ease of correction after dose adjustment, 
we recommend that similar TB programs investigate the 
applicability of TDM within their own settings.  Further 
generalization must be cautiously considered, however, 
because relevant factors that may adversely affect phar-
macokinetics, such as the patient’s weight at the time of 
TDM, concurrent medication use, chronic kidney disease, 
or cirrhosis, were not available in these surveillance data 
for comparison (28–30). Other limitations to the study must 
be taken into account. Blood was collected at 2 hours after 
medication administration to estimate Cmax. A second blood 
collection at 6 hours can additionally distinguish patients 
whose absorption may be delayed secondary to poor gastric 
emptying (4); however, the frequency of delayed absorp-
tion has been rare in other cohorts for which 2 and 6 hour 
measurements were performed (10).
Additionally, given that the prevalence of lower than 
expected drug levels was not known for patients with ad-
equate response to anti-TB therapy, the overall contribu-
tion of pharmacotherapy to the cause of slow response in 
this cohort cannot be fully assessed. Surveillance data did 
not permit comparison of culture positivity in patients who 
met criteria for slow response at the time of TDM matched 
to patients with adequate response for whom TDM was not 
performed. Use of TDM as early as 4 weeks, as was per-
formed in this study, may have selected for patients that 
might otherwise have improved after 8 weeks of therapy 
regardless of other interventions. Lastly, further study may 
ﬁ  nd, given that the cost of TDM (≈$80 US per individual 
drug) may be substantial for some TB control programs, 
that it is more economical to start therapy with increased 
drug dosages for patients at higher risk for slow response.
In summary, routine TDM among patients meeting 
criteria for slow response to TB therapy in Virginia identi-
ﬁ  ed most of those tested to have C2hr levels of rifampin and 
isoniazid below the expected range; many patients also had 
low levels of ethambutol. Most patients with repeat TDM 
following dose adjustment to rifampin and isoniazid had 
levels within the expected range, suggesting a clinically ac-
tionable result. Given the comparative ease of correcting 
low rifampin levels and the shorter duration of therapy in 
those with a correctable rifampin level, this medication is 
particularly appealing to target for programmatic interven-
tion. Further prospective studies should evaluate the beneﬁ  t 
of routine TDM for rifampin early in the treatment course 
among patients with diabetes or of higher initial doses of 
rifampin among all groups at risk for slow response.
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